Record growth at The Wasdell Group
Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.
The Wasdell Group, an outsourcing partner for the pharmaceutical, medical device and clinical development and manufacturing industries, has experienced over 40% revenue growth in the last 24 months, following an increase in demand for its clinical trial, manufacturing and packing services.
Wasdell enter the final quarter of 2018 with a revenue of £41M, a considerable increase compared with £28M in 2016. This record growth has allowed the company to expand its clinical development, manufacturing and packaging capabilities, as well as invest in an on-site laboratory and build its first site outside of the UK.
Martin Tedham, CEO at The Wasdell Group said: “Our strong growth can be largely attributed to the number of pre-clinical development projects that we have recently been awarded, as well as our ongoing work in our manufacturing division.
“It is clear we are becoming more established across the pharmaceutical sector for our efficient service and ability to support customers with end-to-end supply needs. We are not only receiving an influx of new business, but more of our customers are also recognising the advantages of outsourcing more of their operations to Wasdell.”
Following the completion of building work on its new site in Dundalk, Ireland – due to finish in spring 2019 – the company will add 300 new members of staff to its team talking the total number of employees to 1000.
Martin continued: “Despite Brexit looming, our EU & UK business has increased by almost 30% in the last 12 months. We have also strengthened our partnerships with a number of US customers as a result of futureproofing our position as a reliable stepping stone into European market.
“Looking back to 2009 we were turning over just under £2m so to hit our £40M target fills me with a huge amount of pride and gratitude to our customers and our employees. I believe the customer-centric approach Wasdell has always taken, whether it be in delivery of our work or in the investments we have made, has played a huge part in our success today. I can’t wait to see what the future holds.”
Wasdell has ongoing plans to continue investing in its manufacturing and distribution facilities across the UK, especially at its Swindon site which is set to expand in 2019. This next round of investment will cater for the company’s forecasted growth which is estimated to increase by a further 25% by 2020.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance